Title VII: Improving Access to Innovative Medical Therapies
GPTKB entity
Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:legislation
|
| gptkbp:aimsTo |
improve patient access to innovative therapies
streamline FDA approval process |
| gptkbp:amendedBy |
gptkb:Public_Health_Service_Act
|
| gptkbp:approvedBy |
FDA to collect user fees for biosimilars
FDA to collect user fees for generic drugs |
| gptkbp:dateEnacted |
2012
|
| gptkbp:enactedBy |
gptkb:United_States_Congress
|
| gptkbp:focusesOn |
biosimilars
generic drugs biological products |
| gptkbp:goal |
increase competition in pharmaceutical market
reduce drug costs |
| https://www.w3.org/2000/01/rdf-schema#label |
Title VII: Improving Access to Innovative Medical Therapies
|
| gptkbp:partOf |
gptkb:Food_and_Drug_Administration_Safety_and_Innovation_Act
|
| gptkbp:provides |
incentives for drug development
|
| gptkbp:regulates |
approval pathway for biosimilars
approval pathway for generic drugs |
| gptkbp:bfsParent |
gptkb:Affordable_Care_Act
|
| gptkbp:bfsLayer |
5
|